Cell and Gene Therapy Pricing and Reimbursement Summit

Cell and gene therapies are revolutionizing healthcare, offering promising solutions from curative treatments to long-term remission rates. As these treatments enter the market, ensuring fair access while addressing coverage and payment complexities becomes paramount.

Introducing the inaugural Cell and Gene Therapy Pricing and Reimbursement Summit. Biotech, pharma, physicians, healthcare providers, and regulatory and government agencies will unite to address key issues such as the impact of regulatory acts, implementing pricing models, and collaborating on enhanced reimbursement strategies, aiming to expedite the availability of these advanced therapies to patients.

With the recent approval of Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia by bluebird bio; significant strides in healthcare have been made, offering groundbreaking treatments with transformative potential, yet presenting substantial cost challenges. The Inflation Reduction Act and new Cell and Gene Therapy (CGT) Access Model aim to address these cost concerns by proposing innovative pricing models and reimbursement strategies to ensure affordability and widespread access to these life-changing therapies.

Join us this June to discuss the impacts of this legislation and together, we will optimize patient access and propel the success of commercial cell and gene therapy launches.

URLs:
Tickets: https://go.evvnt.com/2238529-2?pid=185
Brochure: https://go.evvnt.com/2238529-3?pid=185

Time: 8:00 AM - 4:15 PM

Speakers: Amar Kelkar, Stem Cell Transplantation Physician, Instructor in Medicine, Dana-Farber Cancer Institute, Carlos Martin, Chief Commercial Officer and Head of International, Rocket Pharma, Frank Zhang, Head Of Commercial, uniQure, Jeff Chaffin, Market Access Strategy Leader, Novan Inc., Jie Zhang, Vice President, Global Value and Access, Cell and Gene, Novartis, Kristin Wolff, Vice President, Market Access, bluebird bio, Laura Okpala. Executive Director, US Reimbursement Policy, Gilead Sciences, Manpreet Sidhu, Executive Director, Global Health Economics, Outcomes Research and Epidemiology, Ultragenyx, Marianne Hamilton Lopez, Senior Research Director, Biomedical Innovation, Duke-Margolis Center for Health Policy, Mark Trusheim, Strategic Director, NEWDIGS, Tufts Medical Center, Matt Feshbach, Founder and Chief Executive Officer, AMBROSE Cell Therapy, Phung Osborn Vice President of Market Access, Orca Bio, Robert Rouse, Head Of Market Access, CSL Behring, Sumeet Panjabi, Senior Director, Real World Value and Evidence, Janssen Pharmaceutical Companies of Johnson and Johnson, Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority, Erica Cischke Vice President, Government Affairs, Alliance for Regenerative Medicine, Jesse Lemberger Sr. Director, US Strategic Pricing, Pfizer